Stratum Biosciences
Category: AI in Healthcare
An AI-powered biotechnology platform that decodes skin biology to discover novel therapeutic actives and optimize topical delivery systems. Stratum Biosciences was founded in 2024. The company is led by Ross Lane Pearlman. Based in 101 6th Ave 3rd floor, New York, NY 10013, USA. Team size: 1-10. Total funding raised: $2.0M. Latest round: Seed round (Mar 2025). Key investors include Harvard Business School Alumni Angels of Greater New York, Skin Angels.
- Founded
- 2024
- Headquarters
- 101 6th Ave 3rd floor, New York, NY 10013, USA
- Team size
- 1-10
- Total funding
- $2.0M
Value proposition
Accelerates the discovery of novel biomarkers and composition-of-matter actives while optimizing bioavailability and skin barrier penetration for high-performance topical products.
Products and solutions
SkinSync™: Proprietary AI-powered discovery platform for skin biology, Stratum BioBank: A repository of over 200,000 real skin tissue samples used for AI training and molecular discovery, Novel Bioactive Pipeline: Development of proprietary composition-of-matter actives and formulations, Biomarker Discovery Services: AI-driven identification of mechanisms for skin, hair, and nail diseases
Unique value
Integrates a massive physical biobank of 200,000+ tissue samples with proprietary AI (SkinSync™) to focus on molecular-level discovery rather than just visual/image-based diagnosis.
Target customer
Global Consumer Packaged Goods (CPG) leaders, pharmaceutical companies, dermo-cosmetic brands, and clinical research institutions.
Industries served
Biotechnology, Dermatology, Consumer Packaged Goods (CPG), Healthcare AI, Pharmaceuticals
Technology advantage
Leverages NVIDIA-backed AI infrastructure and deep dermatological expertise to transform traditionally 'impermeable' molecules into high-performance bioactives with optimized delivery systems.
How they differentiate
Stratum differentiates by combining a massive physical biobank of over 200,000 real skin tissue samples with its proprietary SkinSync™ AI. Unlike competitors that focus primarily on visual/image-based diagnostics or purely computational modeling, Stratum focuses on molecular-level discovery and the optimization of topical delivery systems for 'impermeable' molecules.
Main competitors
Revela (Acquired by Oddity), Haut.AI, InSilico Medicine (Dermatology Division)
Key partnerships
NVIDIA Inception Program (AI infrastructure and support), Johnson & Johnson JLABS (NYC Residency and incubator support), Skin Angels (Dermatology investor network), Harvard Business School Alumni Angels of Greater New York, Global CPG leaders (Validated R&D partnerships for ingredient development)
Notable customers
Global Consumer Packaged Goods (CPG) leaders (Validated R&D partnerships), Dermo-cosmetic brands
Major milestones
Accepted into the NVIDIA Inception Program for AI infrastructure support, Secured residency at Johnson & Johnson’s JLABS @ NYC incubator, Closed $2M Seed funding round in March 2025, Established the Stratum BioBank with 200,000+ tissue samples
Growth metrics
Early-stage startup; currently a resident at Johnson & Johnson’s JLABS @ NYC and a member of the NVIDIA Inception Program.
Market positioning
Upstream R&D-stage biotechnology partner for Global CPG and Pharmaceutical firms.
Geographic focus
North America (Headquartered in New York City)
Patents and IP
Proprietary AI algorithms and composition-of-matter IP for novel actives (specific registration numbers not publicly disclosed as of latest update).
About Ross Lane Pearlman
Dr. Ross Lane Pearlman is a board-certified dermatologist and physician-entrepreneur. He completed his dermatology residency and dual-fellowship training in cosmetic dermatology and dermatologic surgery at Northwestern University. He is the co-founder and Chairman of Skin Angels, the world's largest network of early-stage dermatology investors. His career is defined by the integration of advanced technology and AI into clinical dermatology and skin biology research.
Official website: https://stratumbio.com/